Maraviroc: a review of its use in HIV infection and beyond
SM Woollard, GD Kanmogne - Drug design, development and …, 2015 - Taylor & Francis
The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope
glycoprotein gp120 to the CD4 receptor and/or coreceptors such as CC chemokine receptor …
glycoprotein gp120 to the CD4 receptor and/or coreceptors such as CC chemokine receptor …
Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment
Y Wang, E De Clercq, G Li - Expert opinion on drug metabolism & …, 2019 - Taylor & Francis
Introduction: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are essential
components of highly active antiretroviral therapy against HIV-1 infections. Here, we provide …
components of highly active antiretroviral therapy against HIV-1 infections. Here, we provide …
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society–USA panel
MA Thompson, JA Aberg, P Cahn, JSG Montaner… - Jama, 2010 - jamanetwork.com
Context Recent data regarding the consequences of untreated human immunodeficiency
virus (HIV) infection and the expansion of treatment choices for antiretroviral-naive and …
virus (HIV) infection and the expansion of treatment choices for antiretroviral-naive and …
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society–USA Panel
Importance New data and antiretroviral regimens expand treatment choices in resource-rich
settings and warrant an update of recommendations to treat adults infected with human …
settings and warrant an update of recommendations to treat adults infected with human …
The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic
V Namasivayam, M Vanangamudi… - Journal of medicinal …, 2018 - ACS Publications
Human immunodeficiency virus (HIV) infection is now pandemic. Targeting HIV-1 reverse
transcriptase (HIV-1 RT) has been considered as one of the most successful targets for the …
transcriptase (HIV-1 RT) has been considered as one of the most successful targets for the …
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in …
Writing Group, I Williams, D Churchill… - HIV …, 2014 - Wiley Online Library
1.4 Resource use 1.5 Implications for research 1.6 References 2.0 Recommendations and
auditable outcomes 2.1 Recommendations (GRADE) 2.1. 1 Patient involvement in decision …
auditable outcomes 2.1 Recommendations (GRADE) 2.1. 1 Patient involvement in decision …
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor …
JM Molina, A LaMarca… - The Lancet infectious …, 2012 - thelancet.com
Background Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We
aimed to compare the efficacy and safety of elvitegravir with raltegravir, another HIV-1 …
aimed to compare the efficacy and safety of elvitegravir with raltegravir, another HIV-1 …
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies
J Vingerhoets, L Tambuyzer, H Azijn, A Hoogstoel… - Aids, 2010 - journals.lww.com
Objective: To refine the genotypic and phenotypic correlates of response to the
nonnucleoside reverse transcriptase inhibitor etravirine. Design: Initial analyses identified …
nonnucleoside reverse transcriptase inhibitor etravirine. Design: Initial analyses identified …
Nephrotoxicity of HAART
R Kalyesubula, MA Perazella - AIDS research and treatment, 2011 - Wiley Online Library
Highly active antiretroviral therapy (HAART) and other medical therapies for HIV‐related
infections have been associated with toxicities. Antiretroviral therapy can contribute to renal …
infections have been associated with toxicities. Antiretroviral therapy can contribute to renal …
[PDF][PDF] BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update)
The overall purpose of these guidelines is to provide guidance on best clinical practice in
the treatment and management of adults with HIV infection on antiretroviral therapy (ART) …
the treatment and management of adults with HIV infection on antiretroviral therapy (ART) …